Back to top

Analyst Blog

Medical devices major, St. Jude Medical Inc. (STJ - Analyst Report), presented additional data from the RESPECT clinical trail at the American Stroke Association’s International Stroke Conference 2013. The trial is analyzing the effectiveness of the Amplatzer PFO Occluder for closing a patent foramen ovale or PFO (an opening in the heart) to prevent recurrent strokes in patients, especially those who had experienced cryptogenic stroke.

Data revealed that patients with the device experienced lesser, smaller strokes that were less likely to originate from blood clots passing through the PFO. This reduces the risk of an ischemic stroke. As per the World Health Organization (WHO), strokes affect approximately 15 million people across the globe every year, rendering it to be one of the leading causes of death and long-term disability.

The Amplatzer PFO Occluder technology from St. Jude’s structural heart devices portfolio uses the minimally-invasive transcatheter technique for PFO closure. The company acquired this technology from AGA Medical Holdings, Inc., which it took over in 2010.  The product received CE Mark approval in 1998.  

Earlier, at the 24th Annual Transcatheter Cardiovascular Therapeutics (TCT) conference in Oct 2012, the company released primary data which was hardly statistically significant. However, it trended toward superiority on secondary analysis.

Data indicated that the risk of a stroke was reduced by 46.6% to 72.7% when patients were treated with the Amplatzer PFO Occluder over conventional medical management. Despite missing its primary endpoints, St. Jude plans to submit the product for FDA clearance by mid-2013.

With a market size of $200 million, the Amplatzer PFO closure device represents a major growth driver for St. Jude’s structural heart products business. The franchise grew 3.3% in constant currency in the fourth quarter of 2012. On a constant currency basis, the company expects to record 6%–9% revenue growth in 2013, on the back of a change in sales mix from legacy products to high growth offerings.

The company has a Zacks Rank #3 (Hold). While we remain on the sidelines regarding St. Jude, medical products companies such as Nuvasive Inc. (NUVA), Hanger Inc. (HGR - Analyst Report) and ResMed Inc. (RMD - Analyst Report), which carry a Zacks Rank #1 (Strong Buy), appear impressive.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
SYNAPTICS I… SYNA 78.11 +8.14%
CENTURY ALU… CENX 19.88 +5.74%
GREEN PLAIN… GPRE 39.41 +5.12%
PILGRIM'S P… PPC 28.82 +3.08%
THE PANTRY… PTRY 18.41 +2.79%